ERBB2 and breast carcinoma: A number of previous findings have inferred indirectly that EGFR may form heterocomplexes with other RTKs [14,20,22–24], and recent evidence shows that HER2 inhibitor lapatinib induces HER2/HER3 heterocomplex formation in breast cancer cells [53].